( LOS ANGELES--(BUSINESS WIRE)--July 8 2...)Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference,Health

LOS ANGELES--(BUSINESS WIRE)--July 8, 2007 - Cougar Biotechnology, Inc. (OTCBB:CGRB) today announced that positive Phase I and Phase II data on the Company's prostate cancer drug candidate CB7630 (abiraterone acetate) were presented at the European Society for Medical Oncology (ESMO) Conference, which is currently taking place in Lugano, Switzerland. The data were presented in two oral and poster presentations on Sunday, July 8, as part of the session for genitourinary (prostate) cancer that took place. The poster presentations are further detailed below:

Inhibition of androgen synthesis results in high response rate in castration resistant prostate cancer

The Phase I/II trial of CB7630 was conducted at The Institute of Cancer Research and at The Royal Marsden NHS Foundation Trust in the United Kingdom. In the trial, CB7630 was administered orally, once daily, to chemotherapy-naive patients with castration resistant prostate cancer (CRPC), who had progressive disease despite treatment with LHRH analogues and multiple other hormonal therapies. To date, a total of 47 patients have been treated in the Phase I/II trial, including 15 patients treated in the Phase I portion of the trial and 32 patients treated in the Phase II portion of the trial. Of the 38 patients who were evaluable, all of the patients had radiological evidence of metastatic disease. Moreover, all of the patients had previously failed treatment with LHRH analogs and antiandrogens, while 20 patients (53%) had failed treatment with diethylstilboestrol and 19 patients (50%) had failed treatment with steroids.

In her poster and oral presentation, Dr. Alison Reid from The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust in the United Kingdom reported that CB7630 was well tolerated at doses as high as 2000 mg/day with minimal toxicity. Moreover, no dose limiting toxicity has been observed in the trial to date.

'"/>




Page: 1 2 3 4 5 6
Related medicine technology :

1. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ASCO Annual Meeting
2. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at AUA Annual Meeting
3. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
4. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
7. Prana Biotechnology Presents New Key Findings on PBT2
8. Generex Biotechnology Vaccine Strategy Presented at International Conference in London
9. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
10. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis